Table 2.

Association of Plasma Levels of (A) Adiponectin and (B) Leptin with Coronary Artery Calcification in Tobit Multivariable Models

(A) Adiponectin
	Women	Men	Combined
Variables Adjusted For	Ratio	Ratio	Ratio
	(95% CI)	(95% CI)	(95% CI)
Basic Model (i.e., age, gender, race)	0.60 (0.26–1.39)	1.36 (0.75–2.48)	*
Basic Model, FHx, exercise, meds, FRS	1.22 (0.54–2.78)	1.44 (0.79–2.62)	1.28 (0.79–2.07)
Basic Model, FHx, exercise, meds, MetS	1.13 (0.48–2.69)	1.50 (0.82–2.75)	1.31 (0.80–2.14)
Basic Model, FHx, exercise, meds, FRS, MetS	1.36 (0.58–3.19)	1.55 (0.85–2.84)	1.40 (0.86–2.29)
Above model plus CRP	1.82 (0.76–4.34)	1.51 (0.82–2.76)	1.47 (0.89–2.41)

(B) Leptin
	Women	Men	Combined
Variables Adjusted For	Ratio	Ratio	Ratio
	(95% CI)	(95% CI)	(95% CI)
Basic Model (i.e., age, gender, race)	5.64 (2.37–13.40)	3.26 (1.81–5.87)	3.77 (2.31–6.14)
Basic Model, FHx, exercise, meds, FRS	3.15 (1.36–7.31)	2.21 (1.20–4.08)	2.42 (1.48–3.95)
Basic Model, FHx, exercise, meds, MetS	3.45 (1.42–8.34)	2.25 (1.22–4.16)	2.54 (1.54–4.20)
Basic Model, FHx, exercise, meds, FRS, MetS	3.06 (1.28–7.30)	2.11 (1.13–3.91)	2.30 (1.13–3.91)
Above model plus CRP	1.99 (0.79–4.99)	2.68 (1.40–5.15)	2.31 (1.40–5.15)

Results of Tobit regression are presented as the ratio of increase in CAC score for top vs. bottom quartile of adipokine data. Medications include aspirin, statins, angiotensin converting enzyme inhibitors, FHx = family history, FRS = Framingham Risk Score. MetS = Metabolic syndrome.

^*P<0.01 for gender interaction. CI = confidence interval.